BR112016003019A2 - composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase - Google Patents

composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase

Info

Publication number
BR112016003019A2
BR112016003019A2 BR112016003019A BR112016003019A BR112016003019A2 BR 112016003019 A2 BR112016003019 A2 BR 112016003019A2 BR 112016003019 A BR112016003019 A BR 112016003019A BR 112016003019 A BR112016003019 A BR 112016003019A BR 112016003019 A2 BR112016003019 A2 BR 112016003019A2
Authority
BR
Brazil
Prior art keywords
treating cancer
inhibiting
subject
need
pharmaceutical composition
Prior art date
Application number
BR112016003019A
Other languages
English (en)
Inventor
Lavie Arnon
G Radu Caius
A Nathanson David
M Murphy Jennifer
Wang Jue
E Jung Michael
Satyamurthy Nagichettiar
M Gipson Raymond
Li Zheng
Original Assignee
Univ Illinois
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Univ California filed Critical Univ Illinois
Publication of BR112016003019A2 publication Critical patent/BR112016003019A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase são fornecidos aqui compostos que se ligam a dck e métodos para tratar câncer. 1/1
BR112016003019A 2013-08-13 2014-08-13 composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase BR112016003019A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865468P 2013-08-13 2013-08-13
PCT/US2014/050931 WO2015023776A2 (en) 2013-08-13 2014-08-13 Deoxycytidine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112016003019A2 true BR112016003019A2 (pt) 2017-09-12

Family

ID=52468801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003019A BR112016003019A2 (pt) 2013-08-13 2014-08-13 composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase

Country Status (11)

Country Link
US (2) US9598404B2 (pt)
EP (1) EP3033340B1 (pt)
JP (1) JP6542216B2 (pt)
KR (1) KR102330566B1 (pt)
CN (1) CN105658648B (pt)
AU (1) AU2014306673B2 (pt)
BR (1) BR112016003019A2 (pt)
CA (1) CA2920738A1 (pt)
EA (1) EA036177B1 (pt)
IL (1) IL244029B (pt)
WO (1) WO2015023776A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102330566B1 (ko) * 2013-08-13 2021-11-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 데옥시시티딘 키나제 저해제들
CN108779111B (zh) * 2016-01-08 2021-11-12 加利福尼亚大学董事会 结合脱氧胞苷激酶的化合物
CN106421790B (zh) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用
CN109134354B (zh) * 2018-09-19 2022-03-25 天津科技大学 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺
US20220133735A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014657A1 (en) 2006-07-12 2008-01-17 Beckton Dickinson And Company Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2445898A2 (en) * 2009-06-25 2012-05-02 Amgen, Inc 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
WO2012107465A1 (en) * 2011-02-09 2012-08-16 F. Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
WO2012122368A1 (en) * 2011-03-08 2012-09-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
KR102330566B1 (ko) * 2013-08-13 2021-11-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 데옥시시티딘 키나제 저해제들

Also Published As

Publication number Publication date
EA201690376A1 (ru) 2016-07-29
EA036177B1 (ru) 2020-10-09
US9598404B2 (en) 2017-03-21
CN105658648A (zh) 2016-06-08
CN105658648B (zh) 2020-03-17
AU2014306673B2 (en) 2018-12-06
JP6542216B2 (ja) 2019-07-10
WO2015023776A3 (en) 2015-11-12
EP3033340A2 (en) 2016-06-22
EP3033340A4 (en) 2017-01-25
EP3033340B1 (en) 2019-12-04
US20170204090A1 (en) 2017-07-20
US20160237076A1 (en) 2016-08-18
IL244029B (en) 2019-10-31
WO2015023776A2 (en) 2015-02-19
US9981961B2 (en) 2018-05-29
CA2920738A1 (en) 2015-02-19
KR20160058785A (ko) 2016-05-25
AU2014306673A1 (en) 2016-03-03
IL244029A0 (en) 2016-04-21
KR102330566B1 (ko) 2021-11-25
JP2016530266A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
BR112017020054A2 (pt) anticorpos para icos
HK1215378A1 (zh) 藥物組合物、治療方法及其用途
CL2015002932A1 (es) Inhibidores de proteína quinasa
BR112017023821A2 (pt) moduladores de k-ras
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
EA201591137A1 (ru) Ингибиторы mk2 и их применения
BR112018006696A2 (pt) métodos e sistemas para obter óleo a partir de uma composição de vinhoto
BR112018006140A2 (pt) anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas.
BR112016003019A2 (pt) composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
BR112018011027A2 (pt) técnicas para alocação de casos
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
IL267159B (en) A pharmaceutical preparation containing e7386 given in combination with lanuatinib for the treatment of tumors
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112015023383A2 (pt) compostocomposição farmacêutica; e método de modulação
BR112017024163A2 (pt) compostos bicíclicos
EP3365336A4 (en) Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
EP3020399A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER
IL269769B (en) Mixtures, composition and their use for cancer treatment

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 417/12 , C07D 417/14 , G01N 33/50

Ipc: C07D 417/12 (2006.01), C07D 417/14 (2006.01), ...

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]